Skip to main content
Back to Wellington Management

Wellington Management's Life Science Portfolio

Browse 18 Life Science companies funded by Wellington Management. See funding amounts, founder contacts, and investment details.

Life Science Companies
18
Total Funding in Life Science
$4.5B

Life Science Portfolio Companies (18)

Export
BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics

Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.

San Diego, United States
September 2025
$690.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareLife ScienceOncologyPrecision Medicine

Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.

Boston, United States
July 2024
$150.0M
Series C

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth DiagnosticsLife Science

Element Biosciences develops genomic sequencing and multiomics technologies used in drug discovery, and diagnostic applications.

San Diego, United States
June 2026
Series E

Founder Contacts

30,000+ verified contacts

BiotechnologyLife ScienceMedical

Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.

Cambridge, United States
June 2023
$75.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyLife ScienceTherapeutics

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.

Alameda, United States
June 2026
$25.0M
Grant

Founder Contacts

30,000+ verified contacts

BiotechnologyLife ScienceMedicalTherapeutics

Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders.

San Francisco, United States
May 2026
$1.3B
Post-IPO Debt

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareLife ScienceOncologyTherapeutics

Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.

La Jolla, United States
May 2023
$100.0M
Series C

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyHealth CareLife ScienceMedicalTherapeutics

Freeline is a biotechnology company that develops transformative gene therapies for systemic debilitating diseases.

Stevenage, United Kingdom
March 2022
$26.1M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyGeneticsIndustrial AutomationInnovation ManagementLife ScienceMachine LearningSoftware

Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.

Redwood City, United States
February 2022
$200.0M
Series E

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics

Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.

Munich, Germany
October 2025
$400.6M
Series C

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth CareLife Science

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.

Cambridge, United States
January 2024
$100.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyLife Science

Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).

Cambridge, United States
January 2026
$37.5M
Series A

Founder Contacts

30,000+ verified contacts

BiotechnologyLife ScienceTherapeutics

Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.

Cambridge, United States
November 2025
$500.0M
Post-IPO Secondary

Founder Contacts

30,000+ verified contacts

BiotechnologyClinical TrialsLife SciencePharmaceutical

Centessa Pharmaceuticals is a pharmaceutical company that focuses on drug development to address significant medical needs.

Cambridge, United States
November 2025
$250.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareLife ScienceTherapeutics

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

San Francisco, United States
October 2025
$250.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsLife Science

Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.

Boston, United States
November 2023
$143.8M
Post Ipo Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyLife ScienceTherapeutics

Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.

San Diego, United States
February 2021
$120.0M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyLife ScienceMedical

Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.

Solana Beach, United States
January 2021
$125.0M
Series B

Founder Contacts

30,000+ verified contacts

Explore Wellington Management's Full Portfolio

View all companies funded by Wellington Management across every industry and funding stage.

View Full Wellington Management Portfolio